

## AGENDA FOR THE 91st MEETING OF EAGA

Wednesday 22 February 2012 at 10.30 am

1. **Welcome, introductions, apologies and announcements** 10.30-10.40
2. **Minutes of the previous meeting** – 19 October 2011 (EAGA 90) 10.40-10.45
3. **Matters arising:** 10.45-11.00  
3.1 Report from the Secretariat **Paper EAGA(91)1** For information  
3.2 Correspondence between the Chief Executive of the National Policing Improvement Agency and the EAGA and AGH Chairs **Paper EAGA(91)2**

### Agenda items

4. **Reconstructing the MSM epidemic in the UK: model of HIV transmission, progression and the effect of ART** 11.00-11.30
5. **Impact of the health reforms on HIV prevention, treatment and care (SP 1&2)** 11.30-12.00
6. **EAGA position statement on “HIV transmission within serodiscordant partnerships where the positive partner is on successful antiretroviral therapy”:** draft for discussion **Paper EAGA(91)3** 12.00-12.30
7. **Management of HIV-infected healthcare workers** **Paper EAGA(91)4** 12.30-13.00  
7.1 Feedback from EAGA on consultation questions (SP3)  
7.2 Risk of viral rebound from below 50 copies/ml (SP4&5)  
7.3 HIV elite control – implications for HIV-infected healthcare workers

**LUNCH** 13.00-13.30

8. **HIV testing and follow-up into care** 13.30-13.50  
8.1 Access to and retention in HIV care - national data on loss to follow-up (SP6)  
8.2 Audit of HIV patients lost to follow-up
9. **Update on PrEP initiatives** **Paper EAGA(91)5** 13.50-14.05
10. **Briefing on standards for management of HIV-infected prisoners and immigration detainees** **Paper EAGA(91)6** 14.05-14.15
11. **Update from DH covering testing kit regulations, guidance for Local Authorities on sharing information on STIs, charging regulations, tender for a national HIV prevention programme and sexual health policy framework** 14.15-14.30

12. **Any other business** 14.30-15.00
- 12.1 HIV PEP guidance: do we need an addendum? **Paper EAGA(91)7**
- 12.2 WHO guidance on and hormonal contraception and HIV infection
- 12.3 Review of 2011/12 workplan and planning for 2012/13  
**Paper EAGA(91)8**
13. **Dates of the next meetings: 13 June 2012, 17 October 2012** 15.00 close

.....

**Supporting papers**

**For agenda item 5**

1. a [The new Public Health System](#): summary  
b. [Public Health in Local Government](#): factsheets
2. a Improving outcomes and supporting transparency. [Part 1: A public health outcomes framework for England, 2013-2016](#).  
  
b. Improving outcomes and supporting transparency. [Part 2: Summary technical specifications of public health indicators, January 2012](#).

**For agenda item 7.1**

3. Department of Health. [Management of HIV-infected healthcare workers: a paper for consultation](#). 1 December 2011.
4. Doyle T et al. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2012; 54:729-737.  
<http://cid.oxfordjournals.org/content/early/2012/01/09/cid.cir936.full.pdf+html>
5. Gandhi RJ and Deeks SG. Plasma HIV-1 RNA levels during antiretroviral therapy: how low is low enough?  
<http://cid.oxfordjournals.org/content/early/2012/01/09/cid.cir933.full.pdf+html>

**For agenda item 8**

6. Rice BD et al. Loss to follow-up among adults attending Human Immunodeficiency Virus services in England, Wales and Northern Ireland. Sex Transm Dis 2011; 38:685-90.

**Information papers**

1. Health Protection Agency. [HIV in the United Kingdom: 2011 Report](#). London: Health Protection Services, Colindale. November 2011.

2. Health Protection Agency. [Sexually transmitted infections in men who have sex with men in the UK: 2011 Report](#). London: Health Protection Services, Colindale. November 2011.
3. Benn P et al. UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure (2011). *Int J STD AIDS* 2011; 22:695-708. Available from: <http://www.bashh.org/guidelines>
4. National Institute for Health and Clinical Excellence. [Clinical Guideline 132: Caesarean section](#). November 2011.
5. Hughes JP et al. [Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples](#). *JID* 2012; 205:358-65.
6. Ambrosioni J, Calmy A and Hirschel B. [HIV treatment for prevention](#). *J Int AIDS Soc* 2011; 14:28. Doi:10.1186/1758-2652-14-28
7. [WHO to issue guidance on hormonal contraceptives and HIV](#). Press release 3 February 2012.
8. Hogan CM et al. [The setpoint study \(ACTG A5217\): Effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals](#). *JID* 2012; 205:87-96.
9. Delaugerre C et al. [HIV-1 group N: travelling beyond Cameroon](#). *Lancet* 2011; 378:1894.
10. [Latest UK HIV data reinforce the need for “universal HIV testing” in high prevalence areas](#). *Health Protect Rep* 2011; 5(48).
11. Panel on Antiretroviral Guidelines for Adults and Adolescents. [Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents](#). Department of Health and Human Services. October 14, 2011; 1–167.
12. European AIDS Clinical Society. [Guidelines \(version 6.0\)](#). October 2011.

### **PrEP**

13. Sigma Research. [The Sigma Panel Insight Blast 6: Prospective attitudes to HIV pre-exposure prophylaxis \(PrEP\)](#). London. October 2011.
14. [NIH modifies ‘VOICE’ HIV prevention study in women: oral tenofovir discontinued in clinical trial](#). 28 September 2011.
15. [Microbicide trials network statement on decision to discontinue use of tenofovir gel in VOICE, a major HIV prevention study in women](#). 25 November 2011.
16. Patterson KB et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. *Sci Transl Med* 2011; 3, 112re4.